GO:0097131 cyclin D1-CDK6 complex: Components, Assembly and Research Methods, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0097131 defines the cyclin D1-CDK6 complex, a heterodimeric serine/threonine kinase complex that drives G1-to-S cell-cycle progression.
• The complex is stabilized by viral oncoproteins such as EBNA3C, which enhances cyclin D1 function and promotes G1-S transition.
• Cyclin D1-CDK6 activity is counteracted by CDK inhibitors like p16INK4 and p27Kip1, whose dysfunction is linked to melanoma and esophageal cancer.
• Chemical transformation and oncogenic viruses can alter cyclin D-CDK complex composition and activity, contributing to tumorigenesis.
• The complex is a validated therapeutic target; GSK-3beta regulates cyclin D1 expression and represents a chemotherapy target.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models enable precise dissection of cyclin D1-CDK6 function in cancer and normal cells.
Description
The cyclin D1-CDK6 complex (GO:0097131) is a protein complex consisting of cyclin D1 and cyclin-dependent kinase 6 (CDK6). Cyclins are characterized by periodicity in protein abundance throughout the cell cycle, and CDKs are serine/threonine kinases activated upon binding to a cyclin partner. This complex is a key regulator of the G1-to-S phase transition, and its dysregulation is a hallmark of many cancers. Understanding its assembly, substrates, and regulation is critical for developing targeted therapies. The complex is stabilized and functionally enhanced by viral oncoproteins such as Epstein-Barr virus nuclear antigen 3C (EBNA3C), which facilitates G1-S transition. Conversely, CDK inhibitors like p16INK4 and p27Kip1 negatively regulate the complex, and their inactivation leads to uncontrolled proliferation. Chemical transformation of cells also alters cyclin D-CDK complexes, underscoring their sensitivity to oncogenic insults. Given its central role in cell-cycle control, the cyclin D1-CDK6 complex is a prime target for cancer chemotherapy, with GSK-3beta emerging as a regulator of cyclin D1 expression. This article provides a research-grade overview of GO:0097131, covering its definition, structure, molecular mechanism, key genes, disease links, and experimental models including CRISPR-based approaches.
cyclin D1-CDK6 complex At A Glance
| GO ID | GO:0097131 |
|---|---|
| GO term | cyclin D1-CDK6 complex |
| Ontology | cellular_component |
| Synonym | None |
| Major function | Serine/threonine kinase activity driving G1-to-S cell-cycle transition |
| Complex components | Cyclin D1 (regulatory subunit) and CDK6 (catalytic subunit) |
| Regulatory inhibitors | p16INK4, p27Kip1 |
| Viral modulators | EBNA3C stabilizes and enhances cyclin D1 function |
| Disease relevance | Cancer (melanoma, esophageal, nasopharyngeal, EBV-associated malignancies) |
What Is GO:0097131?
GO:0097131 (cyclin D1-CDK6 complex) is a cellular component ontology term describing a heterodimeric protein complex composed of cyclin D1 and cyclin-dependent kinase 6 (CDK6). Cyclins are regulatory subunits whose abundance oscillates during the cell cycle, while CDKs are serine/threonine protein kinases that become catalytically active only upon binding to a cyclin partner. The cyclin D1-CDK6 complex therefore represents an active kinase holoenzyme that phosphorylates target proteins to drive cell-cycle progression, particularly the G1-to-S transition.
Why Is cyclin D1-CDK6 complex Important in Cell Biology?
The cyclin D1-CDK6 complex is a central driver of the G1-to-S cell-cycle transition, and its hyperactivity is a common feature of human cancers. It integrates mitogenic signals and is targeted by viral oncoproteins such as EBNA3C, which stabilizes cyclin D1 and enhances its function to promote proliferation. Loss of CDK inhibitors like p16INK4 or p27Kip1 unleashes the complex, leading to uncontrolled cell division in melanoma and esophageal cancer. Moreover, chemical transformation alters cyclin D-CDK complexes, highlighting their role in carcinogenesis. The complex is also a therapeutic target: GSK-3beta regulates cyclin D1 expression, and its modulation is being explored for chemotherapy. Thus, understanding GO:0097131 is essential for cancer biology and drug development.
• Drives G1-to-S phase transition, a critical checkpoint in cell-cycle control.
• Stabilized and activated by viral oncoproteins such as EBNA3C, linking it to EBV-associated cancers.
• Inhibited by tumor suppressors p16INK4 and p27Kip1; their loss promotes melanoma and esophageal cancer.
• Altered by chemical carcinogens, contributing to transformation.
• Regulated by GSK-3beta, making it a target for chemotherapy.
• Downstream target of cyclin D1 in nasopharyngeal carcinoma, affecting chloride channel ClC-3.
• Modulated by KSHV cyclin, which affects p27Kip1 levels.
• A key node in oncogenic signaling networks and a validated cancer drug target.
Core Biology of cyclin D1-CDK6 complex
Assembly and Activation
In simple terms: Cyclin D1 and CDK6 join together to form an active kinase that pushes cells to divide.
The cyclin D1-CDK6 complex assembles when cyclin D1 binds to CDK6, inducing a conformational change that activates CDK6's kinase activity. This activation is essential for phosphorylation of retinoblastoma protein (Rb) and subsequent G1-to-S transition. Viral proteins such as EBNA3C can stabilize this complex and enhance its function, promoting cell-cycle progression. Chemical transformation of cells also alters the composition and activity of cyclin D-CDK complexes, indicating that assembly is sensitive to oncogenic signals.
Substrate Phosphorylation and Cell-Cycle Progression
In simple terms: The active complex adds phosphate groups to target proteins, triggering the cell to copy its DNA.
Once active, the cyclin D1-CDK6 complex phosphorylates substrates including Rb, leading to E2F release and expression of S-phase genes. This drives the G1-to-S transition. The complex's activity is opposed by CDK inhibitors; for example, p27Kip1 insufficiently inhibits cyclin D1 in esophageal cancer cells, leading to unchecked proliferation. In nasopharyngeal carcinoma, cyclin D1 regulates the ClC-3 chloride channel, which may contribute to tumor biology.
Regulation by CDK Inhibitors
In simple terms: Brake proteins like p16 and p27 normally slow down the complex, but when they fail, cells divide too fast.
The cyclin D1-CDK6 complex is negatively regulated by INK4 family proteins such as p16INK4, which bind CDK6 and inhibit its activity. Mutations impairing p16INK4 function are associated with familial melanoma. Similarly, p27Kip1 can inhibit cyclin D1-CDK complexes, but in some cancers its inhibitory effect is insufficient. The Kaposi's sarcoma-associated herpesvirus cyclin modulates p27Kip1 levels, further illustrating complex regulation.
Viral Hijacking and Oncogenesis
In simple terms: Some viruses make the complex overactive, helping infected cells grow out of control.
Epstein-Barr virus nuclear antigen 3C (EBNA3C) stabilizes and enhances cyclin D1 function, facilitating G1-S transition and contributing to EBV-associated malignancies. An EBV recombinant deleted for residues 130-159 in EBNA3C deregulates p53/Mdm2 and cyclin D1/CDK6, resulting in apoptosis and reduced proliferation, demonstrating the complex's role in viral oncogenesis. These findings highlight how viral proteins can hijack the cyclin D1-CDK6 complex to promote cancer.
Key Genes Involved in GO:0097131 cyclin D1-CDK6 complex
The following genes and proteins are central to the biology, regulation, and disease relevance of the cyclin D1-CDK6 complex (GO:0097131).
| Gene | Major Role | Research Relevance |
|---|---|---|
| CCND1 | Encodes cyclin D1, regulatory subunit of the complex | Overexpressed in many cancers; target for knockdown/knockout |
| CDK6 | Encodes CDK6, catalytic kinase subunit | Kinase activity drives G1-S; target for point mutations and inhibitors |
| CDKN2A | Encodes p16INK4, inhibitor of CDK6 | Mutations impair inhibition, linked to melanoma |
| CDKN1B | Encodes p27Kip1, CDK inhibitor | Insufficient inhibition of cyclin D1 in esophageal cancer |
| GSK3B | Regulates cyclin D1 expression | Target for chemotherapy; modulates complex levels |
| EBNA3C | Viral protein that stabilizes cyclin D1 and enhances function | Promotes G1-S transition in EBV infection |
| RB1 | Retinoblastoma protein, substrate of the complex | Phosphorylation by CDK6 releases E2F; key checkpoint |
| E2F1 | Transcription factor released upon Rb phosphorylation | Drives S-phase gene expression |
| CLCN3 | Chloride channel ClC-3, downstream target of cyclin D1 | Regulated in nasopharyngeal carcinoma |
| KSHV cyclin | Viral cyclin that modulates p27Kip1 | Affects cell-cycle progression in KSHV infection |
| MDM2 | p53 regulator, deregulated with cyclin D1/CDK6 in EBV mutants | Links complex to apoptosis and proliferation |
| TP53 | Tumor suppressor, indirectly affected by EBNA3C mutants | Deregulated in EBV-associated cancers |
| CDK4 | Related kinase that also partners with cyclin D1 | Parallel pathway; potential redundancy |
| CCND2 | Cyclin D2, related regulatory subunit | May compensate in some contexts |
| CCND3 | Cyclin D3, related regulatory subunit | May compensate in some contexts |
| CDKN1A | p21, CDK inhibitor | Broad CDK inhibitor; context-dependent |
| CDKN2B | p15INK4b, CDK inhibitor | Related to p16INK4; tumor suppressor |
| SKP2 | F-box protein regulating p27Kip1 degradation | Indirectly affects complex activity |
How Is cyclin D1-CDK6 complex Regulated?
The cyclin D1-CDK6 complex is regulated at multiple levels. Its assembly and activity are inhibited by CDK inhibitors such as p16INK4 and p27Kip1. GSK-3beta regulates cyclin D1 expression, thereby controlling complex abundance. Viral proteins like EBNA3C stabilize and enhance cyclin D1 function, promoting G1-S transition. The KSHV cyclin modulates p27Kip1 levels, affecting complex inhibition. Chemical transformation alters cyclin D-CDK complexes, indicating that environmental or carcinogenic signals can disrupt normal regulation. These layers of control ensure proper cell-cycle progression and are frequently subverted in cancer.
cyclin D1-CDK6 complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CCND1 | Breast cancer, lymphoma, nasopharyngeal carcinoma | Knockout or overexpression in cancer cell lines |
| CDK6 | Melanoma, leukemia, breast cancer | Point mutation of kinase domain; knock-in of patient mutations |
| CDKN2A | Familial melanoma | Knockout of p16INK4 in melanocytes; knock-in of melanoma-associated mutations |
| CDKN1B | Esophageal cancer | Knockout of p27Kip1 in esophageal cells; overexpression to test inhibition |
| EBNA3C | EBV-associated malignancies | Knock-in of EBNA3C mutants in B cells; knockout of viral gene |
Cancer
Dysregulation of the cyclin D1-CDK6 complex is a common event in human cancers. Overexpression or stabilization of cyclin D1, or loss of CDK inhibitors, leads to uncontrolled G1-S transition. In familial melanoma, mutations impair p16INK4 function, removing inhibition of CDK6. In esophageal cancer, p27Kip1 insufficiently inhibits cyclin D1, contributing to proliferation. EBV-associated malignancies exploit EBNA3C to stabilize cyclin D1 and enhance its function. Nasopharyngeal carcinoma cells show cyclin D1-dependent regulation of ClC-3, linking the complex to ion transport in cancer.
Viral Oncogenesis
Viruses have evolved mechanisms to hijack the cyclin D1-CDK6 complex. Epstein-Barr virus EBNA3C stabilizes cyclin D1 and enhances its function, facilitating G1-S transition and promoting cell proliferation. An EBV mutant lacking EBNA3C residues 130-159 deregulates p53/Mdm2 and cyclin D1/CDK6, leading to apoptosis and reduced proliferation, underscoring the complex's role in viral oncogenesis. Kaposi's sarcoma-associated herpesvirus cyclin modulates p27Kip1 levels, further illustrating viral interference with cell-cycle control.
Therapeutic Targeting
The cyclin D1-CDK6 complex is a validated target for cancer therapy. GSK-3beta regulates cyclin D1 expression, and its inhibition is being explored as a chemotherapy strategy. CDK6 inhibitors are in clinical use for breast cancer and other malignancies. Understanding the complex's structure and regulation can guide the development of more selective inhibitors. CRISPR-based models can help identify resistance mechanisms and validate combination therapies.
From cyclin D1-CDK6 complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does cyclin D1 loss inhibit G1-S transition? | CCND1 knockout cell lines (e.g., CRISPR-Cas9) |
| How do CDK6 point mutations affect kinase activity? | CDK6 point-mutation knock-in (e.g., kinase-dead or patient variants) |
| Does p16INK4 mutation impair inhibition of CDK6? | CDKN2A knockout or point-mutation knock-in in melanoma cells |
| Can EBNA3C stabilize cyclin D1 in vivo? | EBNA3C knock-in or overexpression in B cells |
| What is the effect of cyclin D1 overexpression on ClC-3? | CCND1 overexpression in nasopharyngeal carcinoma cells |
| Does p27Kip1 insufficiency lead to cyclin D1 hyperactivity? | CDKN1B knockout in esophageal cancer cells |
How to Study the cyclin D1-CDK6 complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Gene expression levels | Quantify CCND1, CDK6, CDKN2A in cancer samples |
| Whole-exome sequencing | Mutations in CDK inhibitors | Identify p16INK4 mutations in melanoma |
| Co-immunoprecipitation | Protein-protein interactions | Detect cyclin D1-CDK6 assembly and EBNA3C binding |
| Kinase activity assay | Phosphorylation of substrates | Measure CDK6 activity in edited cells |
| Flow cytometry | Cell-cycle distribution | Assess G1-S transition after knockout |
| Immunofluorescence | Subcellular localization | Visualize complex in nucleus |
| CRISPR screening | Gene essentiality and resistance | Identify modifiers of cyclin D1-CDK6 dependence |
| Proteomics | Protein abundance and modifications | Profile complex components and interactors |
Genomic and Transcriptomic Profiling
RNA-seq and whole-genome sequencing can identify mutations, copy-number changes, and expression levels of CCND1, CDK6, and CDK inhibitors. These methods are essential for linking genotype to complex activity in cancer samples.
Proteomic and Phosphoproteomic Analysis
Mass spectrometry-based proteomics can quantify cyclin D1-CDK6 complex components and their phosphorylation states. Co-immunoprecipitation followed by mass spectrometry identifies interacting partners and post-translational modifications.
Functional Assays
Cell-cycle analysis by flow cytometry, proliferation assays, and kinase activity assays measure the functional impact of genetic perturbations. These are used to validate CRISPR-edited models.
Imaging and Localization
Immunofluorescence and live-cell imaging can visualize cyclin D1-CDK6 complex localization and dynamics during the cell cycle. This helps confirm assembly and nuclear translocation.
How CRISPR Can Be Used to Study GO:0097131 cyclin D1-CDK6 complex
Knockout
CRISPR-Cas9 knockout of CCND1 or CDK6 can abolish complex formation and inhibit G1-S transition, providing a clean background to study its role in proliferation. Knockout of CDKN2A (p16INK4) or CDKN1B (p27Kip1) can unleash the complex, mimicking cancer-associated loss of inhibition.
Point Mutation
Introducing point mutations in CDK6 (e.g., kinase-dead or patient-derived variants) via CRISPR base editing or homology-directed repair allows precise dissection of kinase-dependent functions. Similarly, melanoma-associated p16INK4 mutations can be knocked in to test their impact on complex inhibition.
Knock-in
Knock-in of tagged cyclin D1 or CDK6 (e.g., GFP or HA) enables live-cell imaging and co-immunoprecipitation studies. Knock-in of viral oncoproteins like EBNA3C can model viral hijacking of the complex.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of CCND1 or CDK6 can drive G1-S transition and transformation. Overexpression models are useful for testing inhibitors and studying downstream targets like ClC-3.
How EDITGENE Supports cyclin D1-CDK6 complex Research
Researchers studying cyclin D1-CDK6 complex-related genes often need to determine whether a candidate gene is causally involved in cell-cycle regulation, cancer progression, or viral oncogenesis. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling rigorous functional validation of genes such as CCND1, CDK6, CDKN2A, and CDKN1B.
Contact EDITGENE today to design your custom CRISPR model for cyclin D1-CDK6 complex research.
Frequently Asked Questions About cyclin D1-CDK6 complex
What is the cyclin D1-CDK6 complex?
The cyclin D1-CDK6 complex (GO:0097131) is a protein complex of cyclin D1 and CDK6 that drives G1-to-S cell-cycle progression.
What genes are involved in the cyclin D1-CDK6 complex?
Key genes include CCND1 (cyclin D1), CDK6, CDKN2A (p16INK4), CDKN1B (p27Kip1), and viral genes like EBNA3C.
How is the cyclin D1-CDK6 complex regulated?
It is inhibited by p16INK4 and p27Kip1, regulated by GSK-3beta, and stabilized by viral proteins like EBNA3C.
What diseases are associated with cyclin D1-CDK6 complex dysfunction?
Cancers such as melanoma, esophageal cancer, nasopharyngeal carcinoma, and EBV-associated malignancies.
How can CRISPR be used to study the cyclin D1-CDK6 complex?
CRISPR knockout, point mutation, knock-in, and overexpression models allow functional dissection of complex components and regulators.
What is the role of p16INK4 in the cyclin D1-CDK6 complex?
p16INK4 inhibits CDK6; mutations impair its function and are linked to familial melanoma.
Does EBNA3C affect the cyclin D1-CDK6 complex?
Yes, EBNA3C stabilizes cyclin D1 and enhances its function, promoting G1-S transition.
What is the clinical significance of cyclin D1-CDK6 complex inhibitors?
CDK6 inhibitors are used in cancer therapy; understanding the complex aids in developing selective inhibitors.
How does p27Kip1 interact with cyclin D1?
p27Kip1 can inhibit cyclin D1-CDK complexes, but its effect may be insufficient in some cancers like esophageal cancer.
What experimental models are available for studying the cyclin D1-CDK6 complex?
Knockout, point mutation, knock-in, and overexpression cell models, as well as CRISPR library screening, are available from EDITGENE.
Conclusion
The cyclin D1-CDK6 complex (GO:0097131) is a pivotal regulator of the G1-to-S cell-cycle transition, with profound implications for cancer biology and viral oncogenesis. Its activity is tightly controlled by CDK inhibitors and modulated by viral proteins, and its dysregulation drives multiple malignancies. CRISPR-based models offer powerful tools to dissect its function and identify therapeutic vulnerabilities. EDITGENE provides comprehensive services to accelerate research on this complex, from knockout to library screening.
References
- 1. Takahashi-Yanaga F et al.. 2008. GSK-3beta regulates cyclin D1 expression: a new target for chemotherapy.. Cell Signal 20(4):581-9 PMID: 18023328
- 2. Shukla SK et al.. 2016. An EBV recombinant deleted for residues 130-159 in EBNA3C can deregulate p53/Mdm2 and Cyclin D1/CDK6 which results in apoptosis and reduced cell proliferation.. Oncotarget 7(14):18116-34 PMID: 26908453
- 3. Anayama T et al.. 2001. Insufficient effect of p27(KIP1) to inhibit cyclin D1 in human esophageal cancer in vitro.. Int J Oncol 18(1):151-5 PMID: 11115553
- 4. Saha A et al.. 2011. Epstein-Barr virus nuclear antigen 3C facilitates G1-S transition by stabilizing and enhancing the function of cyclin D1.. PLoS Pathog 7(2):e1001275 PMID: 21347341
- 5. Zhang H et al.. 2013. The ClC-3 chloride channel protein is a downstream target of cyclin D1 in nasopharyngeal carcinoma cells.. Int J Biochem Cell Biol 45(3):672-83 PMID: 23270726
- 6. Mann DJ et al.. 1999. Modulation of p27(Kip1) levels by the cyclin encoded by Kaposi's sarcoma-associated herpesvirus.. EMBO J 18(3):654-63 PMID: 9927425
- 7. Ranade K et al.. 1995. Mutations associated with familial melanoma impair p16INK4 function.. Nat Genet 10(1):114-6 PMID: 7647780
- 8. Gonzales AJ et al.. 1998. Chemical transformation of mouse liver cells results in altered cyclin D-CDK protein complexes.. Carcinogenesis 19(6):1093-102 PMID: 9667749
